KairosPharma (@KairosPharma) / X

KairosPharma

343 posts

KairosPharma

@KairosPharma

Advancing Immunotherapy Developing A Diversified Pipeline That Targets Resilient Cancers NYSE: $KAPA

Los Angeles, CA

Joined December 2020

KairosPharma
@KairosPharma
Aug 28, 2025
#KairosPharma’s CEO and Chairman, John Yu, M.D., joined @biztv once again to discuss $KAPA's scientific approach, ongoing #clinicaltrials, and upcoming milestones. Check out the interview below: #ClinicalTrial #ProstateCancer #LungCancer #Immunotherapy #KAPA
00:00
4.5K
KairosPharma
@KairosPharma
Sep 3, 2025
$KAPA announces participation & presentation of initial Phase 1 data of ENV105 in non small cell #lungcancer by Principal Investigator, Dr. Karen Reckamp, at the World Lung Cancer Conference. Read more: bit.ly/4nj5WCt #ClinicalTrial #KAPA #ClinicalTrials #WLCC25 @IASLC
3.2K
KairosPharma
@KairosPharma
Sep 4, 2025
#KairosPharma’s CEO & Chairman, John Yu, M.D., spoke with @Phalguni_GD of Drug Device and World on how #KAPA is rethinking cancer drug resistance and advancing new #immunotherapies. Read the full Q&A article here: bit.ly/3I0rsNc #Immunotherapy #CancerResearch $KAPA
1.2K
KairosPharma
@KairosPharma
Aug 21, 2025
$KAPA's CSO, Neil Bhowmick, Ph.D., brings 20+ years of #biochemistry experience filing and prosecuting patents in therapeutics and #biomarker devices. He is also the President of Enviro Therapeutics, Inc., a fully owned subsidiary of #KAPA. Learn more: bit.ly/4lfeJ70
1.3K
KairosPharma
@KairosPharma
Aug 12, 2025
#KairosPharma’s CEO, John Yu, M.D., recently spoke with @ceodotca about $KAPA’s #prostatecancer #clinicaltrial data, upcoming September efficacy data, and expansion into #lungcancer and other tumor types. Learn more: kairospharma.com #ClinicalTrials #KAPA #Immunotherapy
00:00
2.6K
KairosPharma
@KairosPharma
Aug 5, 2025
While #KairosPharma’s CEO and Chairman, John Yu, M.D., leads the $KAPA team, he also serves as Professor of #Neurosurgery and Director Surgical #NeuroOncology at @CedarsSinai Medical Center. Learn more about Dr. Yu and our expert leadership team: bit.ly/4lfeJ70 #KAPA
1.6K
KairosPharma
@KairosPharma
Jul 31, 2025
$KAPA is recruiting for its #ENV105 Phase 1/2 cancer #clinicaltrials. Learn more in the below video & our @NIH websites: #ProstateCancer: bit.ly/44X6gz7 #LungCancer: bit.ly/4l67k9R @LUNGevity, @LiveLung1, @PCFnews, @CedarsSinai, @cityofhope, @huntsmancancer
00:00
367
KairosPharma
@KairosPharma
Nov 12, 2024
Strategic Relationship and Funding: Kairos Pharma leverages a strategic relationship with Cedars-Sinai Medical Center (ranked #2 hospital nationally and #1 in California). This drives clinical trial efficiency, reduces costs, and streamlines therapeutic innovations... $KAPA
904
KairosPharma
@KairosPharma
Aug 14, 2025
Joseph Pantginis, Ph.D., of @HCWCO, updated his coverage on #KairosPharma’s Q2 2025 results, ENV-105 Phase 2 #clinicaltrial advancement, and expected interim efficacy data coming in Q3 2025. #KAPA #ClinicalTrials $KAPA
1.7K
KairosPharma
@KairosPharma
Aug 19, 2025
#KairosPharma’s CEO & Chairman, John Yu, M.D., spoke with @GaurVatsala of @InvezzPortal about the potential of lead drug candidate #ENV105 and how partnerships could aid in the growth of $KAPA. Read more: invezz.com/news/2025/08/1… #KAPA #ProstateCancer #LungCancer #BreastCancer
Interview: Kairos Pharma CEO John Yu on ENV105's potential & partnerships for growth
From invezz.com
1.7K
KairosPharma
@KairosPharma
Aug 7, 2025
#KairosPharma’s ENV-105 was recently featured in an article from @cure_today that covered the top five #prostatecancer highlights for patients in July. Read the full article here: bit.ly/4lkFqHn $KAPA #ClinicalTrials #ENV105 #ClinicalTrial #KAPA
curetoday.com
July Prostate Cancer Highlights: Top 5 Updates Patients Should Know | CURE
New insights highlight how prostate cancer is now managed as a chronic disease, with emerging treatments and real-world data offering renewed hope for patients.
465
KairosPharma
@KairosPharma
Jul 24, 2025
#ICYMI: #KairosPharma announced positive safety results from its ongoing Phase 2 #clinicaltrial of ENV-105 (carotuximab) in patients with metastatic castration-resistant #prostatecancer. Read more: bit.ly/3GYH0jT $KAPA @CedarsSinai, @cityofhope, @huntsmancancer #KAPA
KairosPharma
@KairosPharma
Jul 16, 2025
News Alert! Kairos Pharma Announces Positive Safety Results from Phase 2 Trial of ENV-105 in Advanced Prostate Cancer Read the full release here: loom.ly/0x0y-Y0 NYSE: KAPA #BioPharma #PharmaStock #StockToWatch #Results $KAPA
00:00
investors.kairospharma.com
Kairos Pharma Announces Positive Safety Results from Phase 2 Trial of ENV-105 in Advanced Prostate...
Kairos Pharma, Ltd. (NYSE American:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces positive safety results from its ongoing Phase 2...
345
KairosPharma
@KairosPharma
Sep 2, 2025
#KairosPharma announces that John Yu, M.D., CEO and Chairman, will present a corporate overview at the @HCWCO 27th Annual Global Investment Conference. Learn more: bit.ly/3Vhh4nr $KAPA #KAPA
1K
KairosPharma
@KairosPharma
Jul 30, 2025
#KairosPharma CEO and Chairman, John Yu, M.D., recently spoke with @timsandle of the @digitaljournal about how the $KAPA team is working to develop innovative therapies with the potential to reverse cancer drug resistance. Read more: bit.ly/4kWIDg9 #Immunotherapy #KAPA
215